RFL

About Rafael Holdings, Inc. Class B Common Stock (RFL) Stock

Rafael Holdings, Inc. Class B Common Stock (RFL) closed the 2026-09-18 session at $2.05, down 0.49% versus the previous close (-0.01). The stock opened at $2.05 and traded between $1.95 and $2.10 during that session. Session trading volume was 361K shares. The volume-weighted average price (VWAP) is $2.04.

Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.

Rafael Holdings, Inc. Class B Common Stock has a market capitalization of $106.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. RFL is listed on the XNYS exchange. The company employs approximately 23 people. Rafael Holdings, Inc. Class B Common Stock is headquartered in NEWARK, NJ. The recorded listing date is 2018-03-06.

On this page you can find market RFL stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.

Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.